标题
Investigational drugs for head and neck cancer
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 25, Issue 7, Pages 797-810
出版商
Informa UK Limited
发表日期
2016-04-08
DOI
10.1080/13543784.2016.1175435
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice
- (2016) Y. Lalami et al. CANCER TREATMENT REVIEWS
- Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma
- (2015) E. Massarelli et al. ANNALS OF ONCOLOGY
- Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies
- (2015) A. L. Wong et al. ANNALS OF ONCOLOGY
- Tivantinib (ARQ-197) exhibits anti-tumor activity with down-regulation of FAK in oral squamous cell carcinoma
- (2015) Wei-Hong Xi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients
- (2015) A. A. Osman et al. CANCER RESEARCH
- Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins
- (2015) N. Tanaka et al. CLINICAL CANCER RESEARCH
- MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma
- (2015) S. Mohan et al. CLINICAL CANCER RESEARCH
- Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours
- (2015) S.A. Piha-Paul et al. EUROPEAN JOURNAL OF CANCER
- MEK Inhibitor PD-0325901 Overcomes Resistance to CK2 Inhibitor CX-4945 and Exhibits Anti-Tumor Activity in Head and Neck Cancer
- (2015) Yansong Bian et al. International Journal of Biological Sciences
- Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort.
- (2015) Tanguy Y. Seiwert et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic Landscape of Human Papillomavirus–Associated Head and Neck Cancer and Comparison to Tobacco-Related Tumors
- (2015) D. Neil Hayes et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors
- (2015) Khanh Do et al. JOURNAL OF CLINICAL ONCOLOGY
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- The opposing roles of NOTCH signalling in head and neck cancer: a mini review
- (2015) LF Yap et al. ORAL DISEASES
- A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
- (2015) Antonio Jimeno et al. ORAL ONCOLOGY
- A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors
- (2015) David S. Hong et al. Oncotarget
- The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5
- (2015) Bo Han et al. Oncotarget
- Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches
- (2015) Clint Allen et al. Cancers
- The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck
- (2014) A. Psyrri et al. ANNALS OF ONCOLOGY
- A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
- (2014) A. Jimeno et al. ANNALS OF ONCOLOGY
- TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO)†
- (2014) V. Grünwald et al. ANNALS OF ONCOLOGY
- A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma
- (2014) Dong-Wan Kim et al. BMC CANCER
- Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck
- (2014) Nabil F. Saba et al. CANCER
- What is the best treatment for patients with human papillomavirus-positive and -negative oropharyngeal cancer?
- (2014) Damien Urban et al. CANCER
- Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors
- (2014) Yan Zang et al. CANCER BIOLOGY & THERAPY
- Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors
- (2014) Johanna C. Bendell et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor
- (2014) Takayuki Nakagawa et al. CANCER SCIENCE
- Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies
- (2014) D. W. Bowles et al. CLINICAL CANCER RESEARCH
- The prognostic value of cyclin D1 expression in head and neck squamous cell carcinoma
- (2014) Federico M. Gioacchini et al. EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
- Early investigational drugs that target epidermal growth factor receptors for the treatment of head and neck cancer
- (2014) Gamze Ugurluer et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism
- (2014) Kwai Fung Hui et al. INTERNATIONAL JOURNAL OF CANCER
- mTOR Co-Targeting in Cetuximab Resistance in Head and Neck Cancers Harboring PIK3CA and RAS Mutations
- (2014) Zhiyong Wang et al. JNCI-Journal of the National Cancer Institute
- Wee-1 Kinase Inhibition Overcomes Cisplatin Resistance Associated with High-Risk TP53 Mutations in Head and Neck Cancer through Mitotic Arrest Followed by Senescence
- (2014) A. A. Osman et al. MOLECULAR CANCER THERAPEUTICS
- A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes
- (2013) S. M. Lim et al. ANNALS OF ONCOLOGY
- Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck
- (2013) S. Schmitz et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer
- (2013) Matthew G. Fury et al. CANCER
- Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma
- (2013) S. Lyford-Pike et al. CANCER RESEARCH
- Alteration of cancer stem cell-like phenotype by histone deacetylase inhibitors in squamous cell carcinoma of the head and neck
- (2013) Kazuaki Chikamatsu et al. CANCER SCIENCE
- Targeted therapies for squamous cell carcinoma of the head and neck: Current knowledge and future directions
- (2013) Sandra Schmitz et al. CANCER TREATMENT REVIEWS
- A Phase 1 Study of Everolimus + Weekly Cisplatin + Intensity Modulated Radiation Therapy in Head-and-Neck Cancer
- (2013) Matthew G. Fury et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Whole exome sequencing of adenoid cystic carcinoma
- (2013) Philip J. Stephens et al. JOURNAL OF CLINICAL INVESTIGATION
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Statins and the Risk of Death in Patients With Prostate Cancer
- (2013) Oriana Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition
- (2013) Barbara Burtness et al. LANCET ONCOLOGY
- Bortezomib and SAHA Synergistically Induce ROS-Driven Caspase-Dependent Apoptosis of Nasopharyngeal Carcinoma and Block Replication of Epstein-Barr Virus
- (2013) K. F. Hui et al. MOLECULAR CANCER THERAPEUTICS
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- The mutational landscape of adenoid cystic carcinoma
- (2013) Allen S Ho et al. NATURE GENETICS
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma
- (2013) Julie E. Bauman et al. ORAL ONCOLOGY
- Inhibition of Histone Deacetylase Impacts Cancer Stem Cells and Induces Epithelial-Mesenchyme Transition of Head and Neck Cancer
- (2013) Fernanda S. Giudice et al. PLoS One
- The novel HDAC inhibitor NDACI054 sensitizes human cancer cells to radiotherapy
- (2013) Stephanie Hehlgans et al. RADIOTHERAPY AND ONCOLOGY
- Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
- (2013) V. W. Y. Lui et al. Cancer Discovery
- Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors
- (2013) Matthias Lechner et al. Genome Medicine
- The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response—Biological and Clinical Aspects
- (2013) Michaela Medová et al. Cancers
- The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4
- (2012) Yan Zang et al. Autophagy
- A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)
- (2012) Matthew G. Fury et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies
- (2012) E. M. Karapanagiotou et al. CLINICAL CANCER RESEARCH
- The histone deacetylase inhibitor trichostatin A reduces lysosomal pH and enhances cisplatin-induced apoptosis
- (2012) I. Eriksson et al. EXPERIMENTAL CELL RESEARCH
- Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of
- (2012) Jill Gilbert et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Phase I Trial Using the Proteasome Inhibitor Bortezomib and Concurrent Chemoradiotherapy for Head-and-Neck Malignancies
- (2012) Gregory J. Kubicek et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines
- (2012) Brigette B. Y. Ma et al. INVESTIGATIONAL NEW DRUGS
- Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy
- (2012) George R. Blumenschein et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer
- (2012) Missak Haigentz et al. ORAL ONCOLOGY
- Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck
- (2011) J M del Campo et al. BRITISH JOURNAL OF CANCER
- A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck
- (2011) Athanassios Argiris et al. CANCER
- ERK1/2 Regulation of CD44 Modulates Oral Cancer Aggressiveness
- (2011) N. P. Judd et al. CANCER RESEARCH
- Early Tumor Progression Associated with Enhanced EGFR Signaling with Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer
- (2011) A. Argiris et al. CLINICAL CANCER RESEARCH
- Histone deacetylase-1 and -2 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival
- (2011) Stamatios Theocharis et al. JOURNAL OF ORAL PATHOLOGY & MEDICINE
- HDAC2 promotes cell migration/invasion abilities through HIF-1α stabilization in human oral squamous cell carcinoma
- (2011) Cheng-Chi Chang et al. JOURNAL OF ORAL PATHOLOGY & MEDICINE
- Inhibition of NOTCH3 signalling significantly enhances sensitivity to cisplatin in EBV-associated nasopharyngeal carcinoma
- (2011) Cheuk-Him Man et al. JOURNAL OF PATHOLOGY
- Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1
- (2011) N. Agrawal et al. SCIENCE
- The Mutational Landscape of Head and Neck Squamous Cell Carcinoma
- (2011) N. Stransky et al. SCIENCE
- Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study
- (2011) Jenni K Peltonen et al. Head and Neck Optical Diagnostics Society
- Phase 1 Trial of Gemcitabine With Bortezomib in Elderly Patients With Advanced Solid Tumors
- (2010) Satya V. Bommakanti et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers
- (2010) K. J. Harrington et al. CLINICAL CANCER RESEARCH
- A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer
- (2010) M. P. Lolkema et al. CLINICAL CANCER RESEARCH
- REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer
- (2010) C. Comins et al. CLINICAL CANCER RESEARCH
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Phase I Trial of Bortezomib and Concurrent External Beam Radiation in Patients With Advanced Solid Malignancies
- (2010) Thomas J. Pugh et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT
- (2010) Francesca Bruzzese et al. JOURNAL OF CELLULAR PHYSIOLOGY
- TP53Mutations and Pathologic Complete Response to Neoadjuvant Cisplatin and Fluorouracil Chemotherapy in Resected Oral Cavity Squamous Cell Carcinoma
- (2010) Federica Perrone et al. JOURNAL OF CLINICAL ONCOLOGY
- PS-341 and Histone Deacetylase Inhibitor Synergistically Induce Apoptosis in Head and Neck Squamous Cell Carcinoma Cells
- (2010) J. Kim et al. MOLECULAR CANCER THERAPEUTICS
- A combination treatment with SAHA and ad-p63/p73 shows an enhanced anticancer effect in HNSCC
- (2010) Seon-Hui Shim et al. TUMOR BIOLOGY
- Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
- (2009) C. H. Chung et al. ANNALS OF ONCOLOGY
- Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor
- (2009) A Z Dudek et al. BRITISH JOURNAL OF CANCER
- Proteasome Inhibition Blocks Ligand-Induced Dynamic Processing and Internalization of Epidermal Growth Factor Receptor via Altered Receptor Ubiquitination and Phosphorylation
- (2009) A. H. Kesarwala et al. CANCER RESEARCH
- HDAC inhibitor valproic acid enhances tumor cell kill in adenovirus-HSVtk mediated suicide gene therapy in HNSCC xenograft mouse model
- (2009) Vishal Kothari et al. INTERNATIONAL JOURNAL OF CANCER
- Gastrosplenic Fistula From Hodgkin's Lymphoma
- (2009) Carolyn D. Seib et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictors of Competing Mortality in Advanced Head and Neck Cancer
- (2009) Loren K. Mell et al. JOURNAL OF CLINICAL ONCOLOGY
- The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines
- (2009) Michael B Prystowsky et al. JOURNAL OF PATHOLOGY
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started